Kalehua Capital Management LLC — 13F Holdings & Portfolio

CIK 2106181 · latest 13F-HR filed 2026-05-15

Kalehua Capital Management LLC manages $141.3M in 13F-reported U.S. long-equity assets across 27 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are XFOR (10.88%), BOXX (9.74%), BOXX (8.22%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 2 new positions, exited 0, added to 8, and trimmed 0.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM

$141.3M

Long-equity book

Holdings

27

Distinct positions

Period

2026-03-31

Filed 2026-05-15

Q/Q Activity

+2 / −0 / ↑8 / ↓0

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • Alpha Architect 1-3 Month Box ETF$11.6M +84.3%
  • Veradermics Inc$2.7M +41.6%
  • Inhibikase Therapeutics Inc$1.9M +43.0%
  • ACLARIS THERAPEUTICS INC$1.9M +37.0%
  • Uniqure NV$1.3M +37.5%
Show all 8

Top Trims

  • No decreased positions.
Show all 0

New Positions

  • KORRO BIO INC$1.2M
  • LONGEVERON INC$361.4K
Show all 2

Exited Positions

  • No exits this quarter.
Show all 0
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 X4 Pharmaceuticals Inc XFOR 98420X202 $15.4M 10.88% 3,722,840 SH
2 Alpha Architect 1-3 Month Box ETF BOXX 02072L565 $13.8M 9.74% 118,422 SH
3 EA SERIES TRUST BOXX 02072L565 $11.6M 8.22% 99,856 SH
4 Surrozen Inc SRZN 86889P208 $11.2M 7.94% 385,178 SH
5 Relay Therapeutics Inc RLAY 75943R102 $9.0M 6.35% 901,457 SH
6 Sionna Therapeutics Inc SION 829401108 $7.9M 5.59% 197,072 SH
7 ACLARIS THERAPEUTICS INC ACRS 00461U105 $6.9M 4.86% 1,832,365 SH
8 Veradermics Inc MANE 922967104 $6.5M 4.60% 102,879 SH
9 Inhibikase Therapeutics Inc IKT 45719W205 $6.4M 4.54% 3,821,890 SH
10 Oruka Therapeutics Inc ORKA 687604108 $5.8M 4.11% 118,524 SH
11 Pharvaris NV PHVS N69605108 $5.6M 3.97% 198,772 SH
12 Uniqure NV QURE N90064101 $4.8M 3.37% 291,109 SH
13 Septerna Inc SEPN 81734D104 $4.7M 3.31% 194,544 SH
14 Compass Pathways PLC CMPS 20451W101 $4.5M 3.21% 819,692 SH
15 LeonaBio Inc LONA 04746L203 $4.0M 2.86% 393,701 SH
16 Damora Therapeutics Inc DMRA 36322Q206 $3.6M 2.55% 139,000 SH
17 Gossamer Bio Inc GOSS 38341P102 $3.4M 2.38% 10,236,293 SH
18 MoonLake Immunotherapeutics MLTX 61559X104 $3.3M 2.32% 175,734 SH
19 Tyra Biosciences Inc TYRA 90240B106 $2.9M 2.02% 74,465 SH
20 VERADERMICS INC MANE 922967104 $2.7M 1.91% 42,816 SH
21 PepGen Inc PEPG 713317105 $1.8M 1.25% 1,000,000 SH
22 Instil Bio Inc TIL 45783C200 $1.5M 1.07% 183,030 SH
23 Tenaya Therapeutics Inc TNYA 87990A106 $1.4M 0.98% 2,000,000 SH
24 KORRO BIO INC KRRO 500946108 $1.2M 0.88% 109,376 SH
25 Kalaris Therapeutics Inc KLRS 482929106 $782.3K 0.55% 135,585 SH
26 DiaMedica Therapeutics Inc DMAC 25253X207 $423.0K 0.30% 62,488 SH
27 LONGEVERON INC LOOP 543518104 $361.4K 0.26% 347,539 SH
Filing History
Period Filed AUM Holdings Accession
2026-03-31 2026-05-15 $141.3M 27 0002106181-26-000005
2026-03-31 2026-05-15 $118.6M 23 0002106181-26-000004
2025-12-31 2026-02-13 $101.1M 19 0002106181-26-000003